Comprehensive Approaches in Gastrointestinal Oncology: Focus on Colorectal, Gastric, and Pancreatic Cancer Treatment

Dear Colleagues,

Gastrointestinal oncology increasingly relies on a translational framework that connects molecular discoveries to clinical decision-making. Particularly, in colorectal, gastric, and pancreatic cancer, a coordinated multidisciplinary and translational strategy represents the most effective road to improving patients' prognosis. Preclinical findings are rapidly translated into clinical trials with a biomarker-driven approach, converting biological complexity into personalized therapeutic strategies.

On the other hand, clinical management requires a multidisciplinary team including surgeons, oncologists, gastroenterologists, radiologists, as well as molecular pathologists. Necessarily, this team will be able to integrate all the info about the patient's disease in order to identify the most correct solution to cure it, both for its microscopic and macroscopic aspects.

Certainly, the complexity of these topics requires a lot of different competencies. International collaborations lead to the definition of guidelines and enable data sharing across diverse populations. Scientific publishing diffuses knowledge and in turn stimulates new research and new project.

This Special Issue aims to present and disseminate the most recent advances related to the management of colorectal, gastric, and pancreatic cancer. We consider contributions addressing translational research with clear clinical implications, new insights about staging modalities and multidisciplinary and multimodal treatment strategies, and future perspectives of surgical approaches. Contributions about technological innovations without potential direct patient benefit will be discouraged.   

Topics of interest for publication include, but are not limited to, the following:

Colorectal cancer, gastric cancer, pancreatic cancer, biological staging, clinical staging, early tumors, locally advanced tumors, oligometastatic tumors, neoadjuvant approach, chemotherapy, radiotherapy, immunotherapy, radical surgery, conservative treatment, and targeted therapy.

Prof. Dr. Stefano Rausei
Dr. Georgios D. Lianos
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.